Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18324644 | 0.83 | MAOB (0.42) | JAK2NTRK1TDP1RIPK1MAOB | |
| SCHEMBL16474304 | 0.83 | KDM1A (0.43) | TDP1RIPK1MAOBKDM1ARCOR1 | |
| SCHEMBL4289055 | 0.81 | JAK2 (0.46) | JAK2NTRK1RIPK1MAOBPIK3CD | |
| SCHEMBL17772163 | 0.81 | MAOB (0.40) | TDP1RIPK1MAOBKDM1ARCOR1 | |
| SCHEMBL16474198 | 0.81 | KDM4E (0.39) | JAK2NTRK1TDP1RIPK1MAOB | |
| SCHEMBL457570 | 0.77 | RIPK1 (0.46) | JAK2NTRK1RIPK1MAOBPIK3CD | |
| SCHEMBL454745 | 0.77 | RIPK1 (0.46) | JAK2NTRK1RIPK1MAOBPIK3CD | |
| SCHEMBL4096422 | 0.77 | PIK3CD (0.45) | JAK2NTRK1RIPK1MAOBPIK3CD | |
| SCHEMBL454486 | 0.77 | RIPK1 (0.46) | JAK2NTRK1RIPK1MAOBPIK3CD | |
| SCHEMBL17772162 | 0.76 | RIPK1 (0.50) | TDP1RIPK1MAOBKDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-2451812-B1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9682979-B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2350071-B1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | LTK, TXK, FRK | JAK2 133/4885NTRK1 7/4885TDP1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.